Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

Roberto Latagliata, Massimo Breccia, Carmen Fava, Fabio Stagno, Mario Tiribelli, Luigiana Luciano, Antonella Gozzini, Gabriele Gugliotta, Mario Annunziata, Francesco Cavazzini, Dario Ferrero, Pellegrino Musto, Isabella Capodanno, Alessandra Iurlo, Giuseppe Visani, Monica Crugnola, Elisabetta Calistri, Fausto Castagnetti, Paolo Vigneri, Giuliana Alimena

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

To assess the most important features and clinical impact of pleural effusions, which are a common toxicity during dasatinib treatment and often impair its high efficacy, 172 unselected consecutive patients with chronic myelogenous leukaemia in chronic phase treated in 27 Italian centres, with dasatinib when aged >60years for resistance/intolerance to imatinib, were examined. During treatment, 52/172 patients (30.2%) presented pleural effusion, which was grades 1-2 in 38 patients and grades 3-4 in 14 patients (8.1% of the entire cohort of patients), according to the WHO scale; in 14/52 patients (26.9%), there was a concomitant pericardial effusion. Pleural effusion was recurrent in 25/52 patients (48.0%). Median time from dasatinib to first pleural effusion was 11.0months (interquartile range 3.6-18.6). Eleven patients (6.4%) required permanent dasatinib discontinuation. Only presence of concomitant pulmonary disease (p=0.035) and initial daily dose of dasatinib (140mg vs 100mg, p=0.014) were significantly associated with pleural effusions. There were no differences among patients with or without pleural effusions as concerns response rates and overall survival. Pleural effusions were common in our unselected 'real-life' population of elderly patients but were clinically manageable and did not seem to affect treatment results.

Original languageEnglish
Pages (from-to)363-369
Number of pages7
JournalHematological Oncology
Volume31
Issue number2
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Risk Management
Pleural Effusion
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Incidence
Therapeutics
Dasatinib
Leukemia, Myeloid, Chronic Phase
Pericardial Effusion
Lung Diseases
Survival Rate

Keywords

  • CML
  • Dasatinib
  • Elderly
  • Pleural effusion

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. / Latagliata, Roberto; Breccia, Massimo; Fava, Carmen; Stagno, Fabio; Tiribelli, Mario; Luciano, Luigiana; Gozzini, Antonella; Gugliotta, Gabriele; Annunziata, Mario; Cavazzini, Francesco; Ferrero, Dario; Musto, Pellegrino; Capodanno, Isabella; Iurlo, Alessandra; Visani, Giuseppe; Crugnola, Monica; Calistri, Elisabetta; Castagnetti, Fausto; Vigneri, Paolo; Alimena, Giuliana.

In: Hematological Oncology, Vol. 31, No. 2, 06.2013, p. 363-369.

Research output: Contribution to journalArticle

Latagliata, R, Breccia, M, Fava, C, Stagno, F, Tiribelli, M, Luciano, L, Gozzini, A, Gugliotta, G, Annunziata, M, Cavazzini, F, Ferrero, D, Musto, P, Capodanno, I, Iurlo, A, Visani, G, Crugnola, M, Calistri, E, Castagnetti, F, Vigneri, P & Alimena, G 2013, 'Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia', Hematological Oncology, vol. 31, no. 2, pp. 363-369. https://doi.org/10.1002/hon.2020
Latagliata, Roberto ; Breccia, Massimo ; Fava, Carmen ; Stagno, Fabio ; Tiribelli, Mario ; Luciano, Luigiana ; Gozzini, Antonella ; Gugliotta, Gabriele ; Annunziata, Mario ; Cavazzini, Francesco ; Ferrero, Dario ; Musto, Pellegrino ; Capodanno, Isabella ; Iurlo, Alessandra ; Visani, Giuseppe ; Crugnola, Monica ; Calistri, Elisabetta ; Castagnetti, Fausto ; Vigneri, Paolo ; Alimena, Giuliana. / Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. In: Hematological Oncology. 2013 ; Vol. 31, No. 2. pp. 363-369.
@article{eead28904af64e5192533527295200e8,
title = "Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia",
abstract = "To assess the most important features and clinical impact of pleural effusions, which are a common toxicity during dasatinib treatment and often impair its high efficacy, 172 unselected consecutive patients with chronic myelogenous leukaemia in chronic phase treated in 27 Italian centres, with dasatinib when aged >60years for resistance/intolerance to imatinib, were examined. During treatment, 52/172 patients (30.2{\%}) presented pleural effusion, which was grades 1-2 in 38 patients and grades 3-4 in 14 patients (8.1{\%} of the entire cohort of patients), according to the WHO scale; in 14/52 patients (26.9{\%}), there was a concomitant pericardial effusion. Pleural effusion was recurrent in 25/52 patients (48.0{\%}). Median time from dasatinib to first pleural effusion was 11.0months (interquartile range 3.6-18.6). Eleven patients (6.4{\%}) required permanent dasatinib discontinuation. Only presence of concomitant pulmonary disease (p=0.035) and initial daily dose of dasatinib (140mg vs 100mg, p=0.014) were significantly associated with pleural effusions. There were no differences among patients with or without pleural effusions as concerns response rates and overall survival. Pleural effusions were common in our unselected 'real-life' population of elderly patients but were clinically manageable and did not seem to affect treatment results.",
keywords = "CML, Dasatinib, Elderly, Pleural effusion",
author = "Roberto Latagliata and Massimo Breccia and Carmen Fava and Fabio Stagno and Mario Tiribelli and Luigiana Luciano and Antonella Gozzini and Gabriele Gugliotta and Mario Annunziata and Francesco Cavazzini and Dario Ferrero and Pellegrino Musto and Isabella Capodanno and Alessandra Iurlo and Giuseppe Visani and Monica Crugnola and Elisabetta Calistri and Fausto Castagnetti and Paolo Vigneri and Giuliana Alimena",
year = "2013",
month = "6",
doi = "10.1002/hon.2020",
language = "English",
volume = "31",
pages = "363--369",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "2",

}

TY - JOUR

T1 - Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

AU - Latagliata, Roberto

AU - Breccia, Massimo

AU - Fava, Carmen

AU - Stagno, Fabio

AU - Tiribelli, Mario

AU - Luciano, Luigiana

AU - Gozzini, Antonella

AU - Gugliotta, Gabriele

AU - Annunziata, Mario

AU - Cavazzini, Francesco

AU - Ferrero, Dario

AU - Musto, Pellegrino

AU - Capodanno, Isabella

AU - Iurlo, Alessandra

AU - Visani, Giuseppe

AU - Crugnola, Monica

AU - Calistri, Elisabetta

AU - Castagnetti, Fausto

AU - Vigneri, Paolo

AU - Alimena, Giuliana

PY - 2013/6

Y1 - 2013/6

N2 - To assess the most important features and clinical impact of pleural effusions, which are a common toxicity during dasatinib treatment and often impair its high efficacy, 172 unselected consecutive patients with chronic myelogenous leukaemia in chronic phase treated in 27 Italian centres, with dasatinib when aged >60years for resistance/intolerance to imatinib, were examined. During treatment, 52/172 patients (30.2%) presented pleural effusion, which was grades 1-2 in 38 patients and grades 3-4 in 14 patients (8.1% of the entire cohort of patients), according to the WHO scale; in 14/52 patients (26.9%), there was a concomitant pericardial effusion. Pleural effusion was recurrent in 25/52 patients (48.0%). Median time from dasatinib to first pleural effusion was 11.0months (interquartile range 3.6-18.6). Eleven patients (6.4%) required permanent dasatinib discontinuation. Only presence of concomitant pulmonary disease (p=0.035) and initial daily dose of dasatinib (140mg vs 100mg, p=0.014) were significantly associated with pleural effusions. There were no differences among patients with or without pleural effusions as concerns response rates and overall survival. Pleural effusions were common in our unselected 'real-life' population of elderly patients but were clinically manageable and did not seem to affect treatment results.

AB - To assess the most important features and clinical impact of pleural effusions, which are a common toxicity during dasatinib treatment and often impair its high efficacy, 172 unselected consecutive patients with chronic myelogenous leukaemia in chronic phase treated in 27 Italian centres, with dasatinib when aged >60years for resistance/intolerance to imatinib, were examined. During treatment, 52/172 patients (30.2%) presented pleural effusion, which was grades 1-2 in 38 patients and grades 3-4 in 14 patients (8.1% of the entire cohort of patients), according to the WHO scale; in 14/52 patients (26.9%), there was a concomitant pericardial effusion. Pleural effusion was recurrent in 25/52 patients (48.0%). Median time from dasatinib to first pleural effusion was 11.0months (interquartile range 3.6-18.6). Eleven patients (6.4%) required permanent dasatinib discontinuation. Only presence of concomitant pulmonary disease (p=0.035) and initial daily dose of dasatinib (140mg vs 100mg, p=0.014) were significantly associated with pleural effusions. There were no differences among patients with or without pleural effusions as concerns response rates and overall survival. Pleural effusions were common in our unselected 'real-life' population of elderly patients but were clinically manageable and did not seem to affect treatment results.

KW - CML

KW - Dasatinib

KW - Elderly

KW - Pleural effusion

UR - http://www.scopus.com/inward/record.url?scp=84878972606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878972606&partnerID=8YFLogxK

U2 - 10.1002/hon.2020

DO - 10.1002/hon.2020

M3 - Article

C2 - 22815278

AN - SCOPUS:84878972606

VL - 31

SP - 363

EP - 369

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 2

ER -